SPY415.87+4.42 1.07%
DIA340.44+2.91 0.86%
IXIC14,038.76+180.92 1.31%

BRIEF-Lilly's Mirikizumab Helps Patients Achieve Clinical Remission And Improves Symptoms In Adults With Ulcerative Colitis In 12-Week Phase 3 Induction Study

· 03/16/2021 06:51
BRIEF-Lilly's Mirikizumab Helps Patients Achieve Clinical Remission And Improves Symptoms In Adults With Ulcerative Colitis In 12-Week Phase 3 Induction Study

- Eli Lilly and Co LLY.N:

  • LILLY'S MIRIKIZUMAB HELPS PATIENTS ACHIEVE CLINICAL REMISSION AND IMPROVES SYMPTOMS IN ADULTS WITH ULCERATIVE COLITIS IN 12-WEEK PHASE 3 INDUCTION STUDY

  • ELI LILLY AND CO - PATIENTS TREATED WITH MIRIKIZUMAB MET PRIMARY ENDPOINT OF CLINICAL REMISSION AND ALL KEY SECONDARY ENDPOINTS COMPARED TO PLACEBO

Source text for Eikon: ID:nPn4mlWbYa

Further company coverage: LLY.N


((Reuters.Briefs@thomsonreuters.com;))